CASI Pharmaceuticals Receivables

CASI Pharmaceuticals (CASI) currently reports a receivables of $2.6M as of September 2025. That compares with $11M in the prior-year period — down 76.6% year over year. Use the charts on this page to explore CASI Pharmaceuticals's receivables history and peer comparisons.

CASI Pharmaceuticals's receivables decreased from $11M to $2.6M — a 76.6% year-over-year decrease (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CASI Pharmaceuticals reported $2.6M in receivables as of September 2025. That compares with $11M in the prior-year period — down 76.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $2.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CASI Pharmaceuticals, and consider following CASI for alerts when major investors trade the stock.

CASI Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $2.6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CASI with unrelated industries.